vs

Side-by-side financial comparison of Ceribell, Inc. (CBLL) and Outset Medical, Inc. (OM). Click either name above to swap in a different company.

Outset Medical, Inc. is the larger business by last-quarter revenue ($28.9M vs $24.8M, roughly 1.2× Ceribell, Inc.). Ceribell, Inc. runs the higher net margin — -54.6% vs -67.5%, a 12.9% gap on every dollar of revenue. Outset Medical, Inc. produced more free cash flow last quarter ($-9.7M vs $-11.0M).

Ceribell, Inc. develops and commercializes innovative portable neurodiagnostic medical devices, focused on rapid non-invasive electroencephalogram (EEG) solutions for seizure detection. Its core products serve hospital emergency departments, intensive care units, and long-term care facilities, with primary markets across North America and ongoing global expansion efforts.

Outset Medical, Inc. is a medical technology company focused on developing and commercializing innovative dialysis solutions for patients living with kidney disease. Its flagship Tablo Hemodialysis System supports use in acute care facilities, outpatient clinics, and home settings, serving healthcare providers and patients across the U.S. and select international markets.

CBLL vs OM — Head-to-Head

Bigger by revenue
OM
OM
1.2× larger
OM
$28.9M
$24.8M
CBLL
Higher net margin
CBLL
CBLL
12.9% more per $
CBLL
-54.6%
-67.5%
OM
More free cash flow
OM
OM
$1.2M more FCF
OM
$-9.7M
$-11.0M
CBLL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CBLL
CBLL
OM
OM
Revenue
$24.8M
$28.9M
Net Profit
$-13.5M
$-19.5M
Gross Margin
87.3%
42.4%
Operating Margin
-58.9%
-61.1%
Net Margin
-54.6%
-67.5%
Revenue YoY
-2.0%
Net Profit YoY
24.0%
EPS (diluted)
$-0.35
$0.33

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CBLL
CBLL
OM
OM
Q4 25
$24.8M
$28.9M
Q3 25
$22.6M
$29.4M
Q2 25
$21.2M
$31.4M
Q1 25
$20.5M
$29.8M
Q4 24
$29.5M
Q3 24
$17.2M
$28.7M
Q2 24
$27.4M
Q1 24
$28.2M
Net Profit
CBLL
CBLL
OM
OM
Q4 25
$-13.5M
$-19.5M
Q3 25
$-13.5M
$-17.8M
Q2 25
$-13.6M
$-18.5M
Q1 25
$-12.8M
$-25.8M
Q4 24
$-25.6M
Q3 24
$-10.4M
$-27.9M
Q2 24
$-34.5M
Q1 24
$-39.9M
Gross Margin
CBLL
CBLL
OM
OM
Q4 25
87.3%
42.4%
Q3 25
88.3%
39.4%
Q2 25
88.1%
37.8%
Q1 25
87.9%
37.2%
Q4 24
36.5%
Q3 24
87.3%
34.3%
Q2 24
35.7%
Q1 24
29.2%
Operating Margin
CBLL
CBLL
OM
OM
Q4 25
-58.9%
-61.1%
Q3 25
-64.8%
-53.7%
Q2 25
-70.5%
-53.7%
Q1 25
-69.3%
-55.1%
Q4 24
-74.2%
Q3 24
-57.8%
-83.2%
Q2 24
-112.3%
Q1 24
-131.0%
Net Margin
CBLL
CBLL
OM
OM
Q4 25
-54.6%
-67.5%
Q3 25
-59.6%
-60.6%
Q2 25
-64.4%
-59.0%
Q1 25
-62.4%
-86.7%
Q4 24
-87.0%
Q3 24
-60.6%
-97.5%
Q2 24
-125.8%
Q1 24
-141.8%
EPS (diluted)
CBLL
CBLL
OM
OM
Q4 25
$-0.35
$0.33
Q3 25
$-0.37
$-1.00
Q2 25
$-0.38
$-1.04
Q1 25
$-0.36
$-3.66
Q4 24
$-7.21
Q3 24
$-1.85
$-8.02
Q2 24
$-9.96
Q1 24
$-11.77

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CBLL
CBLL
OM
OM
Cash + ST InvestmentsLiquidity on hand
$159.3M
$168.9M
Total DebtLower is stronger
$96.2M
Stockholders' EquityBook value
$155.3M
$127.0M
Total Assets
$195.8M
$264.5M
Debt / EquityLower = less leverage
0.76×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CBLL
CBLL
OM
OM
Q4 25
$159.3M
$168.9M
Q3 25
$168.5M
$178.6M
Q2 25
$177.4M
$184.1M
Q1 25
$182.7M
$189.0M
Q4 24
$158.7M
Q3 24
$14.1M
$175.6M
Q2 24
$194.8M
Q1 24
$226.9M
Total Debt
CBLL
CBLL
OM
OM
Q4 25
$96.2M
Q3 25
Q2 25
Q1 25
Q4 24
$197.4M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
CBLL
CBLL
OM
OM
Q4 25
$155.3M
$127.0M
Q3 25
$164.1M
$142.4M
Q2 25
$172.2M
$154.8M
Q1 25
$180.9M
$169.9M
Q4 24
$26.8M
Q3 24
$-136.0M
$47.8M
Q2 24
$68.6M
Q1 24
$93.2M
Total Assets
CBLL
CBLL
OM
OM
Q4 25
$195.8M
$264.5M
Q3 25
$199.5M
$277.3M
Q2 25
$207.7M
$288.8M
Q1 25
$213.5M
$301.2M
Q4 24
$275.8M
Q3 24
$47.1M
$292.9M
Q2 24
$314.5M
Q1 24
$346.2M
Debt / Equity
CBLL
CBLL
OM
OM
Q4 25
0.76×
Q3 25
Q2 25
Q1 25
Q4 24
7.36×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CBLL
CBLL
OM
OM
Operating Cash FlowLast quarter
$-10.8M
$-9.5M
Free Cash FlowOCF − Capex
$-11.0M
$-9.7M
FCF MarginFCF / Revenue
-44.2%
-33.7%
Capex IntensityCapex / Revenue
0.7%
0.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-41.6M
$-47.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CBLL
CBLL
OM
OM
Q4 25
$-10.8M
$-9.5M
Q3 25
$-11.1M
$-6.3M
Q2 25
$-7.5M
$-4.8M
Q1 25
$-11.4M
$-25.7M
Q4 24
$-16.5M
Q3 24
$-20.6M
Q2 24
$-33.3M
Q1 24
$-45.9M
Free Cash Flow
CBLL
CBLL
OM
OM
Q4 25
$-11.0M
$-9.7M
Q3 25
$-11.5M
$-6.5M
Q2 25
$-7.6M
$-5.1M
Q1 25
$-11.6M
$-25.8M
Q4 24
$-16.5M
Q3 24
$-21.0M
Q2 24
$-33.5M
Q1 24
$-46.3M
FCF Margin
CBLL
CBLL
OM
OM
Q4 25
-44.2%
-33.7%
Q3 25
-50.8%
-22.0%
Q2 25
-35.9%
-16.3%
Q1 25
-56.4%
-86.7%
Q4 24
-56.1%
Q3 24
-73.1%
Q2 24
-122.2%
Q1 24
-164.3%
Capex Intensity
CBLL
CBLL
OM
OM
Q4 25
0.7%
0.8%
Q3 25
1.6%
0.5%
Q2 25
0.3%
0.9%
Q1 25
0.7%
0.4%
Q4 24
0.1%
Q3 24
1.4%
Q2 24
0.4%
Q1 24
1.3%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CBLL
CBLL

Products$18.8M76%
Subscription$6.0M24%

OM
OM

Consumables Product$13.5M47%
Service And Other Revenue$9.0M31%
Consoles Product$6.4M22%

Related Comparisons